Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30845798 | 0.86 | TGFBR1 (0.44) | PTGS1PTGS2EGLN1HRH4HRH3 | |
| SCHEMBL23534275 | 0.85 | PTGS1 (0.48) | PTGS1PTGS2EGLN1HRH4HRH3 | |
| SCHEMBL23534277 | 0.85 | PTGS1 (0.48) | PTGS1PTGS2EGLN1HRH4HRH3 | |
| SCHEMBL23535036 | 0.85 | PTGS1 (0.48) | PTGS1PTGS2EGLN1HRH4HRH3 | |
| SCHEMBL8607758 | 0.84 | PTGS1 (0.53) | PTGS1PTGS2EGLN1HRH4HRH3 | |
| SCHEMBL21033607 | 0.84 | PTGS1 (0.53) | PTGS1PTGS2EGLN1HRH4HRH3 | |
| SCHEMBL23535045 | 0.84 | PTGS1 (0.47) | PTGS1PTGS2EGLN1HRH4HRH3 | |
| SCHEMBL23571794 | 0.83 | PTGS1 (0.46) | PTGS1PTGS2EGLN1HRH4HRH3 | |
| SCHEMBL3546113 | 0.81 | KDM4E (0.61) | RXFP1KDM4EPOLBNPC1RAB9A | |
| SCHEMBL3540082 | 0.81 | KDM4E (0.61) | RXFP1KDM4EPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| CN-111542523-A | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2020-08-14 | — | — | CN | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| EP-2041133-B1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-13 | — | — | EP | disclosed |
| EP-2041133-A1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003856-A1 | DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PTGS1 2236/4885PTGS2 3251/4885EGLN1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.